Bruker Corp

US · BRKR #1504 by market cap Listed 1970

59.72 -0.78 -1.29%

Live - 5344 symbols - heartbeat 187s ago · 2026-10-08 08:20

Pre-market 60.45 +1.22%

After-hours 60.45 +1.22%

Overnight 59.00 -1.21%

Market cap: 9.10B
P/E (TTM): -85.31
P/B: 3.79
EPS: -0.15
Div yield: 0.33%
52W pos: 79%

Reader sentiment Are you bullish or bearish on BRKR?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Fair

Altman Z-Score is 2.85, in the 1.8-3.0 "grey zone".
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +2.08% YoY

Margins

Gross margin: 45.91%
Operating margin: 6.87%
Net margin: -0.65%

Key ratios & quality

Enterprise value: 10.70B
Altman Z-Score: 2.85

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	1.90B	2.07B	1.99B	2.42B	2.53B	2.96B	3.37B	3.44B
Gross profit	900.00M	995.30M	939.80M	1.21B	1.31B	1.51B	1.65B	1.58B
Selling & admin expenses	449.20M	502.30M	474.50M	562.30M	607.40M	729.40M	893.80M	946.50M
Research & development	173.40M	187.70M	198.00M	220.80M	235.90M	294.80M	376.50M	395.20M
Operating profit	277.40M	305.30M	267.30M	426.50M	462.40M	489.10M	379.20M	236.00M
Pretax profit	244.70M	280.40M	225.80M	393.60M	413.90M	544.20M	206.90M	22.00M
Tax	63.70M	82.40M	64.40M	113.00M	116.40M	117.70M	91.40M	29.30M
Net profit	181.00M	198.00M	161.40M	280.60M	298.50M	428.50M	113.80M	-8.30M
Basic EPS	1	1	1	2	2	3	1	0
Diluted EPS	1.14	1.26	1.02	1.81	1.99	2.90	0.76	-0.15

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	801.40M	797.40M	860.50M	977.20M	823.40M	838.50M
Gross profit	391.20M	357.90M	379.40M	449.20M	379.80M	416.00M
Selling & admin expenses	225.40M	231.40M	242.50M	247.20M	242.10M	238.90M
Research & development	97.10M	100.20M	98.30M	99.60M	101.30M	94.30M
Operating profit	68.70M	26.30M	35.00M	111.80M	36.40M	82.80M
Pretax profit	25.10M	500.00K	-71.80M	68.20M	21.90M	-40.70M
Tax	8.70M	-3.10M	-14.10M	37.80M	2.50M	14.20M
Net profit	16.80M	4.20M	-58.50M	29.20M	15.70M	-50.90M
Basic EPS	0	0	0	0	0	0
Diluted EPS	0.11	0.05	-0.41	0.10	0.02	-0.41

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	1.30B	1.80B	1.93B	2.47B	2.11B	2.16B	2.05B	2.21B
Cash & ST investments	322.40M	684.90M	731.80M	1.17B	645.50M	488.30M	183.40M	298.80M
Inventory	509.60M	577.20M	692.30M	710.10M	800.10M	968.30M	1.07B	1.09B
Total assets	2.13B	2.77B	3.05B	3.65B	3.61B	4.25B	5.81B	6.24B
Total current liabilities	599.30M	645.60M	791.90M	938.50M	914.30M	1.20B	1.28B	1.28B
Short-term debt	18.50M	21.10M	23.50M	130.30M	35.10M	144.50M	64.60M	51.80M
Long-term debt	322.60M	812.80M	842.30M	1.22B	1.20B	1.16B	2.06B	1.85B
Total liabilities	1,200,900,000.00	1,833,300,000.00	2,074,700,000.00	2,565,200,000.00	2,480,000,000.00	2,836,600,000.00	3,991,500,000.00	3,731,100,000.00
Total equity	927.70M	938.20M	974.30M	1.08B	1.13B	1.41B	1.82B	2.51B
Retained earnings	1.10B	1.27B	1.41B	1.66B	1.93B	2.32B	2.41B	2.36B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	2.11B	2.16B	2.35B	2.21B	2.10B	2.23B
Cash & ST investments	184.20M	92.00M	293.10M	298.80M	133.40M	222.50M
Inventory	1.12B	1.22B	1.20B	1.09B	1.12B	1.12B
Total assets	5.93B	6.34B	6.43B	6.24B	6.13B	6.05B
Total current liabilities	1.34B	1.35B	1.27B	1.28B	1.36B	1.20B
Short-term debt	37.70M	55.70M	24.30M	51.80M	8.40M	10.10M
Long-term debt	2.08B	2.38B	1.98B	1.85B	1.66B	1.81B
Total liabilities	4,081,900,000.00	4,473,000,000.00	3,942,500,000.00	3,731,100,000.00	3,627,900,000.00	3,617,100,000.00
Total equity	1.85B	1.87B	2.49B	2.51B	2.50B	2.44B
Retained earnings	2.42B	2.42B	2.35B	2.36B	2.36B	2.29B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	239.70M	213.40M	332.20M	282.40M	274.40M	350.10M	251.30M	134.10M
Depreciation & amortization	64.90M	75.60M	80.50M	89.20M	88.70M	114.90M	183.80M	220.30M
Free cash flow	190.50M	140.40M	235.00M	190.40M	145.20M	243.20M	136.00M	13.90M
Dividends paid	-25.10M	-25.00M	-24.60M	-24.20M	-29.80M	-29.40M	-30.20M	-32.90M
Stock buybacks / issuance	9.40M	-131.40M	-119.90M	-146.30M	-263.10M	-142.80M	409.00M	-2.10M
Ending cash balance	326.30M	681.90M	685.50M	1.07B	648.70M	491.60M	186.70M	303.10M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	65.00M	-127.50M	-33.20M	229.80M	71.20M	-77.40M
Depreciation & amortization	50.40M	56.10M	55.70M	58.10M	58.30M	58.00M
Free cash flow	39.00M	-148.80M	-54.10M	177.80M	47.00M	-106.20M
Dividends paid	-7.70M	-7.60M	0	-17.60M	-18.60M	-18.50M
Stock buybacks / issuance	-10.00M	--	--	3.80M	0	--
Ending cash balance	187.70M	96.20M	297.30M	303.10M	137.60M	189.10M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	22.16	21.87	16.90	27.28	27.16	34.30	7.16	-1.06
ROA %	8.82	8.05	5.42	8.27	8.17	10.87	2.25	-0.37
ROIC %	15.70	13.72	9.06	13.21	12.59	16.89	4.23	0.32
5-year avg ROE %	15.14	18.11	18.76	19.87	23.07	25.50	22.56	18.97
EBIT margin %	13.57	14.30	12.09	16.87	16.99	18.91	7.57	2.39
FCF / sales %	10.05	6.77	11.82	7.87	5.74	8.20	4.04	0.40
Current ratio	2.18	2.78	2.43	2.63	2.31	1.80	1.60	1.73
Quick ratio	1.13	1.62	1.35	1.69	1.36	0.92	0.69	0.81
Debt / assets	16.02	31.78	29.94	38.19	35.17	32.46	38.67	32.73
LT debt / equity	35.98	94.82	92.52	118.04	110.91	89.68	122.43	81.05
Interest coverage	20.42	18.53	16.68	28.52	26.71	34.18	5.32	1.36
Revenue CAGR (3Y) %	5.29	8.75	4.02	8.45	6.88	14.26	11.66	10.74
Net income CAGR (3Y) %	20.93	8.69	26.15	15.53	14.57	39.37	-25.82	--
FCF CAGR (3Y) %	-0.78	14.43	28.52	-0.02	1.13	1.15	-10.61	-54.25

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	4.93	4.43	-1.12	-1.06	-1.71	-5.11
ROA %	1.53	1.30	-0.38	-0.37	-0.60	-1.73
ROIC %	3.41	2.78	0.40	0.32	-0.30	-2.10
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	6.28	5.61	2.17	2.39	2.26	1.12
FCF / sales %	5.07	1.43	--	0.40	0.63	1.84
Current ratio	1.57	1.61	1.85	1.73	1.55	1.85
Quick ratio	0.66	0.62	0.84	0.81	0.65	0.83
Debt / assets	35.63	38.41	31.21	32.73	27.26	30.15
LT debt / equity	114.25	131.91	81.59	81.05	67.90	76.20
Interest coverage	3.86	3.45	1.15	1.36	1.32	0.64
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Diversified

Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics, is the largest reported line at 37.01% of revenue, across 5 reported segments.
No single line clears half of revenue; Bruker Scientific Instrument (BSI) Nano is next at 31.16%, spreading the business across more than one real driver.

Revenue breakdown most recent period

Business

Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics,37.01%

Bruker Scientific Instrument (BSI) Nano31.16%

Bruker Scientific Instruments (BSI) BioSpin23.34%

Bruker Energy & Supercon Technologies (BEST)8.85%

Quote time 2026-10-08 08:20:21 · For reference only, not investment advice and not tailored to your situation.